Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Idelalisib - Gilead Sciences

X
Drug Profile

Idelalisib - Gilead Sciences

Alternative Names: CAL-101; GS-1101; IDELA; Zydelig

Latest Information Update: 10 Nov 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Calistoga Pharmaceuticals
  • Developer Augusta University; Calistoga Pharmaceuticals; Celgene Corporation; Gilead Sciences; Merck Sharp & Dohme; National Cancer Institute (USA)
  • Class Antineoplastics; Purines; Quinazolinones; Small molecules
  • Mechanism of Action Phosphatidylinositol 3 kinase delta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic lymphocytic leukaemia; Follicular lymphoma
  • Phase III Non-Hodgkin's lymphoma
  • Phase II Hodgkin's disease; Mantle-cell lymphoma; Waldenstrom's macroglobulinaemia
  • Phase I/II Non-small cell lung cancer
  • No development reported Diffuse large B cell lymphoma; Myelofibrosis; Pancreatic cancer
  • Discontinued Allergic rhinitis; Solid tumours

Most Recent Events

  • 27 Sep 2022 Gilead Sciences terminates a phase III trial in Follicular lymphoma (Second-line therapy or greater) in USA, Australia, Canada, Czech Republic, France, Israel, Italy, Poland, Romania, Spain, United Kingdom due to enrollment challenges faced by the company (PO) (NCT02536300)
  • 14 Jan 2022 Launched for Chronic lymphocytic leukaemia (Combination therapy, First-line therapy) in United Kingdom (PO) as of January 2022 as of January 2022
  • 14 Jan 2022 Launched for Chronic lymphocytic leukaemia (Combination therapy, Second-line therapy or greater) in New Zealand, United Kingdom, Australia (PO) as of January 2022
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top